Clinical trials: Advanced Cirrhosis
Advanced Chronic Liver Disease, Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.
- Trial name
- NCT06974565
- Testing
- AZD2389, Quinidine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Advanced Chronic Liver Disease, Healthy Participants
A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants
The purpose of this study is to measure the effect of multiple doses of AZD2389 on the pharmacokinetics (PK) of midazolam, caffeine, and bupropion in healthy participants.
- Trial name
- CRIOLLO (NCT06973005)
- Testing
- AZD2389, Midazolam, Caffeine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-alcoholic Fatty Liver Disease, Liver Fibrosis
Early Detection of Advanced Fatty Liver Disease
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the western world, affecting one in every three subjects.
- Trial name
- NCT03608748
- Where
- Israel
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Non Alcoholic Fatty Liver Disease
Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease
The purpose of this randomized clinical trial is to evaluate the utility of noninvasive markers for the detection of advanced fibrosis in patients newly diagnosed with Non-alcoholic Fatty Liver Disease (NAFLD) by ultrasound.
- Trial name
- NCT01874249
- Testing
- Electronic detailed information, NAFLD Score, Transient elastography
- Where
- Mexico
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Fundación Clínica Médica Sur